Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;63(1):332-342.
doi: 10.2337/db13-1144. Epub 2013 Oct 2.

The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Affiliations

The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Zheng Ye et al. Diabetes. 2014 Jan.

Abstract

Epidemiological evidence supports a direct and causal association between lipoprotein(a) [Lp(a)] levels and coronary risk, but the nature of the association between Lp(a) levels and risk of type 2 diabetes (T2D) is unclear. In this study, we assessed the association of Lp(a) levels with risk of incident T2D and tested whether Lp(a) levels are causally linked to T2D. We analyzed data on 18,490 participants from the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort that included adults aged 40-79 years at baseline 1993-1997. During an average 10 years of follow-up, 593 participants developed incident T2D. Cox regression models were used to estimate the association between Lp(a) levels and T2D. In Mendelian randomization analyses, based on EPIC-Norfolk combined with DIAbetes Genetics Replication And Meta-analysis data involving a total of 10,088 diabetes case participants and 68,346 control participants, we used a genetic variant (rs10455872) as an instrument to test whether the association between Lp(a) levels and T2D is causal. In adjusted analyses, there was an inverse association between Lp(a) levels and T2D: hazard ratio was 0.63 (95% CI 0.49-0.81; P trend = 0.003) comparing the top versus bottom quintile of Lp(a). In EPIC-Norfolk, a 1-SD increase in logLp(a) was associated with a lower risk of T2D (odds ratio [OR] 0.88 [95% CI: 0.80-0.95]). However, in Mendelian randomization analyses, a 1-SD increase in logLp(a) due to rs10455872, which explained 26.8% of the variability in Lp(a) levels, was not associated with risk of T2D (OR 1.03 [0.96-1.10]; P = 0.41). These prospective findings demonstrate a strong inverse association of Lp(a) levels with risk of T2D. However, a genetic variant that elevated Lp(a) levels was not associated with risk of T2D, suggesting that elevated Lp(a) levels are not causally associated with a lower risk of T2D.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The association between deciles of baseline Lp(a) distribution and incident type 2 diabetes and coronary heart disease in the EPIC-Norfolk study Lp(a): lipoprotein(a); Confidence intervals (CIs) were calculated using a floating absolute risk technique; Hazard ratios were adjusted for age as underlying timescale, sex, BMI, alcohol, smoking status, systolic and diastolic blood pressure, physical activity, education level, and family history of diabetes (only for T2D) or family history of CHD (only for CHD); formula image: CHD; ■: T2D
Figure 2
Figure 2
Instrumental variable analysis estimate of the association of genetically elevated circulating Lp(a) and risk of T2D using rs10455872 as an instrument

Comment in

References

    1. Tsimikas S, Hall JH. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60:716–721. - PubMed
    1. Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23:133–140. - PubMed
    1. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44:2301–2306. - PubMed
    1. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102(5):1082–1085. - PubMed
    1. The Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423. - PMC - PubMed

Publication types

LinkOut - more resources